Can Probiotics Actually Help Psoriasis? What a 2026 Meta-Analysis Found

Can Probiotics Actually Help Psoriasis? What a 2026 Meta-Analysis Found

Psoriasis affects hundreds of millions of people worldwide, and for many, standard therapies only go so far. In recent years, a growing body of research has focused on an unlikely ally: the gut. Specifically, scientists are asking whether probiotics — live microorganisms that confer a health benefit when consumed in adequate amounts — can meaningfully reduce psoriasis severity. A wave of high-quality systematic reviews and meta-analyses published in 2025 and 2026 now gives us the clearest picture yet. Here's what the evidence actually says.

What exactly are PASI and DLQI, and why do they matter for reading this research?

These two scores are the universal measuring sticks of psoriasis research, and understanding them is essential for interpreting any clinical data. The Psoriasis Area and Severity Index (PASI) — a 0–72 composite score rating redness, thickness, scaling, and body-surface coverage of plaques — and the Dermatology Life Quality Index (DLQI) — a 10-item patient-reported questionnaire capturing how skin disease affects daily life, work, and relationships — appear in virtually every modern trial. The PASI score is widely used to grade psoriatic lesion severity and treatment response; a score between 5 and 10 signals moderate disease, above 10 signals severe disease, and a 75% reduction in PASI (called "PASI 75") is the FDA benchmark for approving new psoriasis treatments. When you see a study reporting changes in PASI and DLQI, you're seeing the two most clinically meaningful windows into whether a treatment works — both objectively and from the patient's own perspective.

What does the most comprehensive 2026 review actually conclude?

The headline finding is encouraging. Probiotics are associated with significantly reduced PASI scores, increased PASI 75 response rates, lowered inflammatory biomarkers (CRP, TNF-α, IL-6), and improved DLQI. This conclusion comes from a 2026 umbrella review published in the Journal of Nutrition and Metabolism by Ayuningtyas et al., which synthesized findings across five systematic reviews and meta-analyses covering hundreds of adult psoriasis patients. Crucially, not all probiotic regimens performed equally: greater effectiveness was found with multistrain probiotics, treatment durations of 12 weeks or more, and studies conducted in Asia. Safety was not a concern — most studies reported good tolerability and minimal side effects.

How large are the actual numerical improvements — and are they clinically meaningful?

Size matters when interpreting pooled data, and here the numbers are striking. A meta-analysis synthesizing data from 15 randomized controlled trials (RCTs) encompassing 1,423 participants found that probiotics significantly improved PASI (Mean Difference: −4.05, 95% CI: −6.73 to −1.38; p < 0.0001) and DLQI (MD: −5.74, 95% CI: −11.45 to −0.03; p = 0.0001) — a performance that outstripped both synbiotics and systemic pharmacological therapies such as anti-TNF-α and anti-interleukin agents in the same comparison. A separate, widely cited meta-analysis by Wei et al. found similar directional results: probiotic supplementation produced a standardized mean difference of −1.40 in PASI and −0.92 in DLQI compared with placebo, indicating clinically meaningful improvement. A third meta-analysis, published in Frontiers in Medicine (2024), confirmed that compared with placebo, PASI was significantly reduced in the probiotic group (MD −3.09, 95% CI −5.04 to −0.74, p = 0.01), as was CRP (MD −2.36, 95% CI −2.77 to −1.95, p < 0.0001). In plain terms: across thousands of patients and dozens of trials, probiotics consistently move the needle on disease severity and quality of life.

How do probiotics actually work against psoriasis — what is the gut-skin axis?

The mechanism isn't magic — it's immunology. The gut-skin axis refers to the bidirectional communication network linking intestinal microbiota to systemic immune responses and, ultimately, to skin inflammation. Probiotics function primarily by modulating immune responses, enhancing gut epithelial barrier integrity, and producing anti-inflammatory metabolites; specific strains can interact directly with dendritic cells, regulatory T cells, and macrophages, suppressing pro-inflammatory cytokines such as IL-17 and TNF-α, which are central to the pathogenesis of psoriasis. From the patient side, researchers hypothesize that the benefits of probiotics in psoriasis stem from immunomodulatory effects on the gut microbiome, such as increasing Foxp3+ regulatory T cells and reducing apoptosis-mediated skin inflammation. There is also a structural component: probiotics demonstrated superior systemic anti-inflammatory responses (including TNF-α and IL-17 suppression) and enhanced gut barrier integrity. A leakier gut allows bacterial lipopolysaccharides (LPS) to spill into systemic circulation, triggering the very inflammatory cascades that drive plaque formation — repairing that barrier is therefore a key upstream intervention.

Are all probiotic formulations equally effective, or does strain selection matter?

Strain selection makes a significant difference. The probiotics studied consisted of both single-strain and multistrain formulations, sometimes combined with prebiotics (making them synbiotics). The pattern is consistent across reviews: multistrain combinations outperform single strains. Improvements in PASI scores and reductions in inflammatory markers such as CRP, IL-6, and TNF-α have been observed in RCTs investigating the effects of various probiotics, including Lactobacillus and Bifidobacterium species. A 2025 PRISMA-compliant systematic review spanning PubMed, Scopus, and Cochrane databases — which screened 688 unique records and ultimately included eight studies — found that probiotic or synbiotic supplementation, either alone or as an adjunct to topical or systemic therapy, was associated with reductions in both PASI and DLQI scores. Duration also matters: trials running 12 weeks or longer tend to produce stronger outcomes, suggesting that microbiome remodelling is a slow, cumulative process rather than a quick fix.

What are the honest limitations of this evidence base?

The science is promising — but it is not yet definitive, and intellectual honesty requires acknowledging where the gaps lie. A high overlap among included reviews was observed (corrected covered area = 38.64%), which should be considered when interpreting the findings. Not every trial is a success story either: one 2023 study by Suriano et al. assessed adjuvant probiotics in 103 psoriasis patients and failed to demonstrate that Lactobacillus rhamnosus could improve PASI or DLQI (p = 0.620). Heterogeneity in strain selection, dosing, treatment duration, baseline disease severity, and patient ethnicity all complicate apples-to-apples comparisons. Furthermore, subgroup analyses suggest that gut microbiota-targeted therapy performs significantly better in Asian psoriasis patients than in European and American populations — a finding that points toward the role of baseline microbiome composition, diet, and genetics in modulating response. Larger, well-powered, pre-registered RCTs with standardised protocols are still needed before probiotics can be formally incorporated into clinical guidelines.

What does the 2026 evidence mean practically for people living with psoriasis?

Probiotics, particularly multistrain formulations, show potential as a safe and effective adjuvant therapy for reducing psoriasis severity and improving patient quality of life. The keyword is adjuvant — meaning alongside, not instead of, prescribed care. Probiotics have shown promising results in suppressing inflammatory pathways and alleviating psoriasis symptoms by modulating gut microbiota; after several weeks of intervention, patients showed microbiome changes along with reduced levels of inflammatory biomarkers and psoriasis severity. Patients with psoriasis considering probiotic supplementation should discuss this with their dermatologist or gastroenterologist, particularly regarding strain choice, dosage, and realistic timelines — typically at least three months. The gut-skin axis is no longer a fringe theory; it is a robust area of investigation with growing clinical evidence to match.

Q: What is a PASI score, and what counts as a good improvement?
PASI (Psoriasis Area and Severity Index) ranges from 0 to 72 and measures the extent and severity of psoriatic plaques. A reduction of 75% from baseline — known as PASI 75 — is the gold-standard benchmark used by the FDA to define treatment efficacy in clinical trials.
Q: How long do you need to take probiotics before seeing results in psoriasis?
The current meta-analytic evidence suggests that treatment durations of 12 weeks (approximately 3 months) or longer are associated with greater improvements in PASI and DLQI scores. Shorter courses may produce smaller or less consistent effects.
Q: Are single-strain or multistrain probiotics better for psoriasis?
Multiple reviews consistently indicate that multistrain probiotic formulations — those containing several Lactobacillus and Bifidobacterium species — tend to outperform single-strain products. Synbiotics (probiotics combined with prebiotics) are also under active investigation.
Q: Can probiotics replace standard psoriasis treatments like biologics or topical steroids?
No. Current evidence positions probiotics as adjuvant (add-on) therapy, not a replacement for established treatments. Most trials have tested probiotics alongside topical steroids or systemic agents, not as a standalone cure. Always discuss any supplement use with your healthcare provider.
Q: Are probiotics safe for people with psoriasis?
Across the clinical trials reviewed, probiotics were generally well tolerated. Most studies reported good safety profiles with minimal adverse events. However, individuals with compromised immune systems or serious comorbidities should seek medical guidance before starting any probiotic regimen.
Q: Why does the gut microbiome affect skin conditions like psoriasis?
Through the gut-skin axis, intestinal dysbiosis (microbial imbalance) can compromise gut barrier integrity, allowing inflammatory compounds such as lipopolysaccharides (LPS) to enter systemic circulation. This triggers immune cascades — involving IL-17, TNF-α, and other cytokines — that promote the skin inflammation characteristic of psoriasis.
Q: Do probiotics help with the quality-of-life impact of psoriasis, not just the visible plaques?
Yes. Multiple meta-analyses report significant improvements in DLQI (Dermatology Life Quality Index) — a patient-reported measure covering itch, pain, social embarrassment, and daily functioning — alongside PASI reductions, suggesting that the benefit extends beyond visible skin clearance.

Sources:

Back to Skin Care

You may also like

View all